Ikarian Capital’s Soleno Therapeutics SLNO Stock Holding History

Ikarian Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-528,900	Closed	-$24.5M	–	207
2025 Q4	$24.5M	Buy	528,900 +352,800	+200%	+$19.3M	1.91%	12
2025 Q3	$11.9M	Sell	176,100 -23,900	-12%	-$1.77M	1.2%	20
2025 Q2	$16.8M	Sell	200,000 -43,000	-18%	-$3.22M	3.22%	5
2025 Q1	$17.4M	Buy	+243,000	New	+$11.8M	2.14%	7
2024 Q4	–	Sell	-110,000	Closed	-$5.55M	–	202
2024 Q3	$5.55M	Buy	+110,000	New	+$5.27M	0.77%	33
2024 Q2	–	Sell	-81,100	Closed	-$3.47M	–	150
2024 Q1	$3.47M	Buy	81,100 +59,900	+283%	+$2.71M	0.38%	65
2023 Q4	$853K	Buy	+21,200	New	+$603K	0.08%	104
2020 Q3	–	Sell	-70,000	Closed	-$2.33M	–	206
2020 Q2	$2.33M	Buy	+70,000	New	+$3.03M	0.19%	100

Ikarian Capital's SLNO Position: Q2 2026 in Review

Ikarian Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 344,123 shares — an estimated $11.5M sold.

Ikarian Capital first reported a position in SLNO in Q2 2020 and held it in 15 quarters. The position peaked at $24.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Ikarian Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 344,123 Soleno Therapeutics shares in Q2 2026, an estimated $11.5M.
Ikarian Capital first reported a position in Soleno Therapeutics in Q2 2020 and held it in 15 quarters.
Ikarian Capital's Soleno Therapeutics position peaked at $24.2M in Q1 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.